苏金单抗治疗中重度斑块状银屑病的真实世界有效性与安全性:PROSPECT研究
PROSPECT是一项正在进行的24周单队列非干预性研究,纳入1988例决定接受苏金单抗300mg的中重度银屑病患者。第24周时,基线开始治疗者的PASI75/90/100应答率分别为86.1%、68.5%和39.7%,未观察到意外安全性信号,有效性与安全性同2/3期临床试验相当。
要点
- 苏金单抗300mg在真实世界中第24周PASI75达86.1%。
- 44.3%患者记录有伴随治疗,过渡期中位14.0–44.5天。
- 未观察到意外安全性信号,与临床试验一致。
核心结论
- 苏金单抗在真实世界中对中重度斑块状银屑病的有效性和安全性与2/3期临床试验相当。
研究设计与样本
- PROSPECT为正在进行的24周单队列非干预性研究,纳入1988例决定接受苏金单抗300mg的中重度银屑病患者。
主要发现
- 1238/1988(62.4%)为男性,平均年龄48.1±13.7岁,基线平均PASI评分17.7±12.5。
- 90.9%受试者既往接受过系统治疗,44.3%记录有伴随治疗。
- 从既往外用、传统系统及生物制剂治疗过渡的中位持续时间分别为14.0、30.0和44.5天。
- 第24周时,基线开始苏金单抗治疗者的PASI75/90/100应答率分别为86.1%、68.5%和39.7%。
- 未观察到意外安全性信号。
临床怎么用
- 真实世界数据支持苏金单抗300mg用于中重度斑块状银屑病,疗效与临床试验一致。
- 临床中需关注既往治疗过渡期及伴随用药情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate-to-severe psoriasis. Trial protocols specify transition periods and prohibit concomitant psoriasis medication. Data are therefore needed on secukinumab effectiveness and safety in routine clinical practice. OBJECTIVES: The PROSPECT study assesses prior and concomitant psoriasis treatments and transition periods in subjects receiving secukinumab. Here, we report interim effectiveness and safety data for secukinumab in the context of prior and concomitant treatments. METHODS: PROSPECT is an ongoing 24-week, single-cohort, non-interventional study. Subjects with moderate-to-severe psoriasis with a decision to receive secukinumab 300 mg were included. RESULTS: Of 1988 subjects, 1238/1988 (62.4%) were male, and mean age was 48.1 ± 13.7 years. Mean baseline Psoriasis Area and Severity Index (PASI) score was 17.7 ± 12.5. 90.9% of subjects had prior systemic treatment. Concomitant treatment was recorded in 44.3% of subjects. Median duration of transition period was 14.0, 30.0 and 44.5 days from prior topical, conventional systemic and biologic treatments. At Week 24, PASI75/90/100 was reached by 86.1%, 68.5% and 39.7% of subjects who started secukinumab treatment at baseline. No unexpected safety signals were observed. CONCLUSION: PROSPECT provides a large prospective real-world analysis of secukinumab treatment and includes prior and concomitant use of psoriasis treatments in subjects receiving secukinumab in a real-world setting. Secukinumab effectiveness and safety were comparable to that seen in the phase 2/3 secukinumab clinical trial programme.
引用
- Thaçi D, Körber A, von Kiedrowski R, et al. Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. J Eur Acad Dermatol Venereol. 2019. PMID: 31541554. doi:10.1111/jdv.15962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。